Evidence map›Paper›PMID 42055629›Full record

ArticleCancer genomics & proteomics

Transcriptome-based Deep Learning Model for Predicting Gemcitabine and Cisplatin Chemotherapy Response in Urothelial Carcinoma: Development and External Validation.

Juwon Kang, Hyun Jung Lee, Sang-Bo Oh, Jong Kil Nam, Tae Un Kim, Hwaseong Ryu, Yong Kan Ki, Jihoon Kang, Yi Rang Kim, Jeong Hoon Lee and 3 more

Abstract read
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Juwon Kang *ONCOCROSS Co., Ltd., Seoul, Republic of Korea.
Hyun Jung Lee *Department of Pathology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Sang-Bo OhMedical Oncology and Hematology, Department of Internal medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Jong Kil NamDepartment of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Tae Un KimDepartment of Radiology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Hwaseong RyuDepartment of Radiology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Yong Kan KiDepartment of Radiation Oncology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Jihoon KangONCOCROSS Co., Ltd., Seoul, Republic of Korea.
Yi Rang KimONCOCROSS Co., Ltd., Seoul, Republic of Korea.
Jeong Hoon LeeDepartment of Radiology, Stanford University School of Medicine, Stanford, CA, U.S.A.
Junjeong ChoiYonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon, Republic of Korea.
Yun Jeong HongDepartment of Neurology, Uijeongbu St. Mary's Hospital, Catholic University of Korea, Seoul, Republic of Korea.
Kwonoh ParkDepartment of Pathology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea; parkkoh@daum.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimChemotherapy with gemcitabine and cisplatin remains the cornerstone of treatment for advanced urothelial carcinoma (UC), yet response rates vary significantly among patients. Predicting treatment response is crucial to avoid unnecessary toxicity and optimize therapeutic strategies. This study aims to develop a deep learning model leveraging RNA sequencing data to predict chemotherapy response in UC patients. MATERIALS AND

methodsWe developed a deep learning model using RNA sequencing gene expression data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus to predict chemotherapy (gemcitabine and cisplatin) response in UC patients. The model was externally validated using an independent cohort from the Pusan National University Yangsan Hospital. Model interpretation was performed through gene ontology and survival analyses using predictions from TCGA samples not included in the training set.

resultsThe deep learning model demonstrated excellent predictive performance, achieving 94.7% accuracy in the training dataset and 90.0% accuracy in external validation. Gene ontology analysis revealed four key functional clusters associated with chemotherapy response: DNA damage response, cell cycle regulation, kinesins/microtubule dynamics, and mitotic cytokinesis. Notably, the model showed significant prognostic value in early-stage, with predicted responders displaying markedly better survival outcomes (

conclusionOur transcriptome-based deep learning approach offers a promising computational strategy for predicting chemotherapy response in urothelial carcinoma. By integrating high-dimensional RNA-seq data and advanced machine learning techniques, we provide a potential decision-support tool for personalized treatment planning.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCisplatinDeep LearningDeoxycytidineTranscriptomeUrinary Bladder NeoplasmsFemaleGemcitabineHumansMalePrognosisCisplatinDeoxycytidineGemcitabinechemotherapy responsecisplatindeep learninggemcitabineprecision oncologyRNA sequencingUrothelial carcinoma

Identifiers

PMID42055629
PMCPMC13133846

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.